Recs

0
Player Avatar TMFCane (60.25) Submitted: 12/17/2012 3:16:16 AM : Outperform Start Price: $43.21 MRK Score: -4.16

Januvia and Janumet are poised to explode with the diabetes market. Suvorexant and odanacatib both look good, and keeping all its divisions together (rather than spinning them off a la Abbott and Pfizer) should allow Merck to capitalize on growth segments. This company's done well in compensating for Singulair's loss.

Featured Broker Partners


Advertisement